{"entity":{"id":"nct05050942","kind":"trial","name":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","aka":[],"tldr":"A phase 3 trial of CAM2029 (octreotide subcutaneous depot) run by Camurus AB, active.","summary":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET is a phase 3 interventional study registered as NCT05050942 by Camurus AB, with 332 participants enrolled, started 2021-10-22. Conditions listed: Gastro-enteropancreatic Neuroendocrine Tumor. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05050942","url":"https://clinicaltrials.gov/study/NCT05050942"}],"tags":["ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["cam2029"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05050942","phase":"3","setting":"A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET","sponsor":"Camurus AB","enrolled":332,"outcomes":[]},"route":"/trials/nct05050942/","neighbours":{"drug":[{"id":"cam2029","kind":"drug","name":"CAM2029 (octreotide subcutaneous depot)","route":"/drugs/cam2029/"}]}}